AI Bridges Gap Between Patients and Cures

The United States, a leader in biomedical innovation, faces a critical challenge with its clinical trial system, which lags significantly behind medical advancements. This delay prevents many patients from accessing potentially life-saving treatments for conditions like cancer, Alzheimer's, and rare genetic disorders. Currently, fewer than 5% of Americans participate in clinical trials, with patient recruitment being the primary cause of delays, impacting up to 80% of enrollment timelines.

Artificial intelligence offers a groundbreaking solution to this problem by integrating the separate systems of patient care and medical research. Oracle is developing a digital bridge using its extensive electronic health record platform, a leading electronic data capture platform for clinical research, secure cloud infrastructure, and advanced AI. This initiative aims to enable physicians nationwide to identify and connect eligible patients with clinical trials more efficiently.

This integration promises to create a continuously learning healthcare system, accelerating the transition of discoveries from the lab to the bedside. It supports broader research participation, generates robust real-world evidence, and strengthens post-market monitoring. Responsible deployment of AI, with human oversight, strong privacy protections, and transparent governance, is crucial. The FDA's real-time clinical trials initiative is a start, but a more ambitious approach is needed to encourage AI's use in patient identification and trial processes without compromising safety.